BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38263486)

  • 21. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
    Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
    Saha D; Rabkin SD; Martuza RL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
    Motomura K; Natsume A; Kishida Y; Higashi H; Kondo Y; Nakasu Y; Abe T; Namba H; Wakai K; Wakabayashi T
    Cancer; 2011 Apr; 117(8):1721-30. PubMed ID: 21472719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q; Berglund AE; Macaulay RJ; Etame AB
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
    Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
    PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
    Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
    J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
    Bhaskaran D; Savage J; Patel A; Collinson F; Mant R; Boele F; Brazil L; Meade S; Buckle P; Lax S; Billingham L; Short SC
    BMC Cancer; 2024 Jan; 24(1):83. PubMed ID: 38225549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
    Wang Y; Pan L; Sheng XF; Chen S; Dai JZ
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e23-9. PubMed ID: 24571331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
    Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
    J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
    Tomar MS; Kumar A; Srivastava C; Shrivastava A
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188616. PubMed ID: 34419533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
    Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
    Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
    [No Abstract]   [Full Text] [Related]  

  • 36. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
    J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
    Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
    J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
    Bassi R; Dei Cas M; Tringali C; Compostella F; Paroni R; Giussani P
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
    Lum LG; Al-Kadhimi Z; Deol A; Kondadasula V; Schalk D; Tomashewski E; Steele P; Fields K; Giroux M; Liu Q; Flaherty L; Simon M; Thakur A
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.